Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 82

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 82
---
 focused on the discovery and development of innovative human microbiome-based therapeutics. The human microbiome is an array of more than 100 trillion microorganisms that live on and in our bodies, creating a community of symbiotic, commensal and pathogenic bacteria, all of which call the human body home. These microbes have numerous beneficial functions relevant to supporting life, such as digesting food, preventing disease-causing pathogens from invading the body, and synthesizing essential nutrients and vitamins. Numerous studies have shown the connection between the human microbiome and various medical disorders, and the search for microbiome therapies and treatments is a rapidly growing focus for biotherapeutics research and development.
 
Biomica focuses on the development of human-microbiome based therapies utilizing either rationally-designed microbial consortia or small molecule approaches for (i) immuno-oncology (ii) gastrointestinal inflammatory, or GI, related disorders, and (iii) antimicrobial resistance, or AMR, an antibiotic resistant bacteria.
 
In December 2024, Biomica initiated two new discovery-stage programs:
 

a)   Anti-Obesity – Designed to harness the microbiome to support weight loss and effective management of obesity.
------------------------------------------------------------------------------------------------------------------

b)   Longevity – Focused on leveraging the microbiome to promote healthy aging by targeting age-related processes throughout the
                                                              lifespan.                                                         
--------------------------------------------------------------------------------------------------------------------------------
Market
 
Biomica’s product development is currently focused in three main markets:
 
Immune-Oncology
 
In oncology, checkpoint inhibitor antibodies, including those targeting the programmed cell death protein/ligand 1, or PD-1/PD-L1 pathways, block the tumor’s ability to suppress the immune response. They have significantly improved the treatment of many cancers. The global cancer immunotherapy market size was estimated at $126.19 billion in 2023 and is projected to hit around $296.01 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033, according to a report published by Nova One Advisor Research6, which is not incorporated by reference herein.
 
Even in cancers, where checkpoint inhibition is considered the frontline standard of care, a significant percentage of the patients do not respond to PD-1 + CTLA-4 inhibitor combination and a portion of responders relapse within a few years. In all approved cancer indications, agents with differentiated immune mechanisms of action may be complementary to checkpoint inhibitors by both augmenting existing effects and testing alternative pathways of immun